131 related articles for article (PubMed ID: 6122229)
1. Solubilized dopamine/neuroleptic receptors (D2-type).
Madras BK; Davis A; Chan B; Seeman P
Prog Neuropsychopharmacol; 1981; 5(5-6):543-8. PubMed ID: 6122229
[No Abstract] [Full Text] [Related]
2. Ascorbate injury and EDTA (or manganese) protection of D2-dopamine receptors.
Chan B; Seeman P; Davis A; Madras BK
Eur J Pharmacol; 1982 Jun; 81(1):111-6. PubMed ID: 6126367
[TBL] [Abstract][Full Text] [Related]
3. Modulation of dopamine receptor binding by ascorbic acid.
Madras BK; Chan B
Adv Biochem Psychopharmacol; 1983; 37():275-87. PubMed ID: 6138950
[No Abstract] [Full Text] [Related]
4. Solubilization of neuroleptic/dopamine receptors of human brain striatum.
Davis A; Madras B; Seeman P
Eur J Pharmacol; 1981 Mar; 70(3):321-9. PubMed ID: 6112153
[TBL] [Abstract][Full Text] [Related]
5. Characterization of solubilized dopamine receptors from dog striatum.
Gorissen H; Aerts G; Laduron P
FEBS Lett; 1979 Apr; 100(2):281-5. PubMed ID: 37113
[No Abstract] [Full Text] [Related]
6. Hallucinogen binding to dopamine/neuroleptic receptors.
Whitaker PM; Seeman P
J Pharm Pharmacol; 1977 Aug; 29(8):506-7. PubMed ID: 19605
[No Abstract] [Full Text] [Related]
7. Dopamine D4 receptors bind inactive (+)-aporphines, suggesting neuroleptic role. Sulpiride not stereoselective.
Seeman P; Van Tol HH
Eur J Pharmacol; 1993 Mar; 233(1):173-4. PubMed ID: 8097160
[TBL] [Abstract][Full Text] [Related]
8. A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects.
Reitz AB; Bennett DJ; Blum PS; Codd EE; Maryanoff CA; Ortegon ME; Renzi MJ; Scott MK; Shank RP; Vaught JL
J Med Chem; 1994 Apr; 37(8):1060-2. PubMed ID: 7909336
[No Abstract] [Full Text] [Related]
9. Dopamine D2 receptors selectively labeled by a benzamide neuroleptic: [3H]-YM-09151-2.
Niznik HB; Grigoriadis DE; Pri-Bar I; Buchman O; Seeman P
Naunyn Schmiedebergs Arch Pharmacol; 1985 Jun; 329(4):333-43. PubMed ID: 2863760
[TBL] [Abstract][Full Text] [Related]
10. D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics.
Farde L; Wiesel FA; Nordström AL; Sedvall G
Psychopharmacology (Berl); 1989; 99 Suppl():S28-31. PubMed ID: 2573104
[TBL] [Abstract][Full Text] [Related]
11. Neuroleptic/dopamine receptors: elevation and reversal.
List S; Seeman P
Adv Biochem Psychopharmacol; 1980; 24():95-101. PubMed ID: 6105811
[No Abstract] [Full Text] [Related]
12. Similarities and dissimilarities between dopamine and neuroleptic receptors: further evidence for type 1 and type 2 dopamine receptors in the CNS.
Spano PF; Memo M; Govoni S; Trabucchi M
Adv Biochem Psychopharmacol; 1980; 24():113-21. PubMed ID: 6105769
[No Abstract] [Full Text] [Related]
13. Dopamine-sensitive adenylate cyclase and dopamine/neuroleptic receptor binding: effect of neuroleptic drugs.
Marshall AM; Mishra RK
Adv Biochem Psychopharmacol; 1980; 24():153-7. PubMed ID: 6105772
[No Abstract] [Full Text] [Related]
14. Dopamine agonist high-affinity state in solubilized D2 receptors in striatum, but not in anterior pituitary.
Dumbrille-Ross A; Seeman P
Biochem Pharmacol; 1987 Jul; 36(13):2095-9. PubMed ID: 2955789
[TBL] [Abstract][Full Text] [Related]
15. High-affinity binding sites for neuroleptic drugs in human peripheral blood lymphocytes and their relation to dopamine receptors. A long-standing controversy.
Vile JM; Strange PG
Biochem Pharmacol; 1995 Mar; 49(6):747-53. PubMed ID: 7702632
[No Abstract] [Full Text] [Related]
16. Selective binding of YM-09151-2, a new potent neuroleptic, to D2-dopaminergic receptors.
Terai M; Usuda S; Kuroiwa I; Noshiro O; Maeno H
Jpn J Pharmacol; 1983 Aug; 33(4):749-55. PubMed ID: 6138453
[TBL] [Abstract][Full Text] [Related]
17. Purification and properties of brain neuroleptic-binding proteins.
Sartania NA; Abutidze KD; Mikeladze DG
J Protein Chem; 1989 Jun; 8(3):339-40. PubMed ID: 2571344
[No Abstract] [Full Text] [Related]
18. Dopamine receptors, neuroleptics, and schizophrenia.
Snyder SH
Am J Psychiatry; 1981 Apr; 138(4):460-4. PubMed ID: 6111227
[TBL] [Abstract][Full Text] [Related]
19. Neuroleptic binding to muscarinic M2 receptors of normal human heart in vitro and comparison with binding to M1 and dopamine D2 receptors of brain.
Neeper R; Richelson E; Nelson A
Neuropharmacology; 1991 May; 30(5):527-9. PubMed ID: 1678146
[TBL] [Abstract][Full Text] [Related]
20. Quantitative electroencephalographic frequencies and relative neuroleptic receptor affinities in schizophrenia.
Small JG; Milstein V; Malloy FW; Miller MJ
Biol Psychiatry; 1996 Jun; 39(11):986-8. PubMed ID: 9162214
[No Abstract] [Full Text] [Related]
[Next] [New Search]
